|
Identification of a novel CTNNA1 germline mutation predisposing to melanoma: Genotype and functional effects. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Janssen-Cilag; Novartis |
|
Brigitte M Bressac-de Paillerets |
No Relationships to Disclose |
|
Arnaud De La Fouchardiere |
Consulting or Advisory Role - Amgen (I); Bayer (I); Brystol-Myers-squibb (I); Lilly (I); Pierre Fabre (I); Roche (I); Roche Molecular Diagnostics; SERVIER (I); Shire (I) |
Research Funding - Roche (I) |
Travel, Accommodations, Expenses - Amgen (I); Bristol-Myers-Squibb (I); Celgene (I); Roche (I); SERVIER (I) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Foundation Medicine |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Foundation Medicine; MSD; Novartis; Pierre Fabre |